Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             62 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A novel strategy for the identification by phage panning in vivo of ligands specific for cells in the extra-vascular space Finger, A.N.
 2001
 37 S3 p. S10-
1 p.
 artikel
2 Apoptosis resistance and immune escape mechanisms of bladder cancer cells Willert, Patricia L.
 2001
 37 S3 p. S11-
1 p.
 artikel
3 Applications of CpG oligonucleotides in cancer therapy Hartmann, Gunther
 2001
 37 S3 p. S19-
1 p.
 artikel
4 Assessing the cancerostatic potency of rViscumin towards human tumor xenografts and cell lines in vitro Möckel, B.
 2001
 37 S3 p. S12-
1 p.
 artikel
5 A strong and rapid immunosuppression by extracellular ROS- cleaving enzymes (GSH-peroxidase, catalase, MnSOD, CuZnSOD) gives evidence for a permanent, O2 illegible??? and O2 2− maintained intercellular cross talk, even in the resting state ROS- cleaving enzymes as novel immunosuppressants and HO2 and H2O2 as well as NH3 and polyamines as novel “second messengers” Leskovar, P.
 2001
 37 S3 p. S14-
1 p.
 artikel
6 A TGFβRII frameshift mutation derived CTL epitope recognised by HLA-A2 restricted CD8+ T cells Sæterdal, Ingvil
 2001
 37 S3 p. S27-
1 p.
 artikel
7 Biological tumour regression and dormancy: a new therapetic approach from tumour stability analysis Roy, Prasun K
 2001
 37 S3 p. S13-
1 p.
 artikel
8 CD4+ and DC requirements for optimal CD8+ CTL induction against tumors Melief, Cornelis JM
 2001
 37 S3 p. S5-
1 p.
 artikel
9 CpG ODNs enhance recall and prmary specific human CTL responses Hornung, V.
 2001
 37 S3 p. S25-
1 p.
 artikel
10 CpG ODNs enhance recall and prmary specific human CTL responses Hornung, V.
 2001
 37 S3 p. S25-
1 p.
 artikel
11 Effective immunotherapy of large established tumors with CpG oligonucleotides and dendritic cells in murine tumor models Rall, K.
 2001
 37 S3 p. S28-
1 p.
 artikel
12 Effective immunotherapy of large established tumors with CpG oligonucleotides and dendritic cells in murine tumor models Rall, K.
 2001
 37 S3 p. S28-
1 p.
 artikel
13 Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells Decker, Thomas
 2001
 37 S3 p. S21-
1 p.
 artikel
14 Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells Decker, Thomas
 2001
 37 S3 p. S5-
1 p.
 artikel
15 Establishment of a stable mixed allogeneic chimerism by the successive injection of a 1:1 mixture of mature, lifespan-preprogrammed donor plus recipient T cells or PBMCS, followed by a 1:1 mixture of immature, non-DNA-premanipulated bone marrow or stem cells of the same donor : host origin Leskovar, P.
 2001
 37 S3 p. S14-
1 p.
 artikel
16 Expression of cytokine receptors on AML blasts Graf, M.
 2001
 37 S3 p. S9-
1 p.
 artikel
17 Expression of HLA-class I and II molecules is maintained on leukemic blasts from patients with acute myelogenous leukemia (AML) and the costimulatory molecule CD 86 is upregulated Vollmer, M.
 2001
 37 S3 p. S25-
1 p.
 artikel
18 Generation of HER2-reactive T helper and T killer cells: implementation for T cell therapy Bernhard, Helga
 2001
 37 S3 p. S6-
1 p.
 artikel
19 Heat shock proteins and dendritic cells: effects on maturation and antigen presentation Kuppner, M.
 2001
 37 S3 p. S31-
1 p.
 artikel
20 Her-2 expression is of independent prognostic significance in pNO prostate cancer undergoing curative radiotherapy Fosså, A.
 2001
 37 S3 p. S26-
1 p.
 artikel
21 Hsp70-peptide activated autologous NK cells in the immunotherpay of cancer — a clinical pilot study Krause, S.
 2001
 37 S3 p. S13-
1 p.
 artikel
22 Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma Huhn, Michael
 2001
 37 S3 p. S12-
1 p.
 artikel
23 Identification of new immunogenic antigens in acute and chronic myeloid leukemias (AML / CML) for the development of vaccines Schmitt, Michael
 2001
 37 S3 p. S19-
1 p.
 artikel
24 Immune deficiencies in breast cancer Wiltschke, C.
 2001
 37 S3 p. S6-
1 p.
 artikel
25 Immune restoration in cancer patients by cyclooxygenase-inhibition in vitro and in vivo Lang, S.
 2001
 37 S3 p. S9-
1 p.
 artikel
26 Immunotherapy of malignant diseases with peptide pulsed dendritic cells Brossart, Peter
 2001
 37 S3 p. S31-
1 p.
 artikel
27 Immunotherapy of malignant diseases with peptide pulsed dendritic cells Brossart, Peter
 2001
 37 S3 p. S31-
1 p.
 artikel
28 Inactivation of the INK4 gene cluster in mantle cell lymphomas - standardization and initial analysis of differential methylation patterns of cell cycle regulators Hutter, G.
 2001
 37 S3 p. S10-
1 p.
 artikel
29 Induction of an effective immune response against tumor-cell-spheroids induced by the trifunctional antibody BiUIII (anti-EpCAM X anti-CD3) Walz, A.
 2001
 37 S3 p. S15-
1 p.
 artikel
30 Induction of T cell immune response after DNA immunization with human cytochrome P450 CYP1B1 — a potential cancer therapy Ramstedt, Urban
 2001
 37 S3 p. S27-
1 p.
 artikel
31 Intradermal ras peptide vaccination of colorectal cancer patients: a randomized trial of two different dose levels of mutant ras peptides with- or without GM-CSF Gjertsen, Marianne K.
 2001
 37 S3 p. S26-
1 p.
 artikel
32 Introduction 2001
 37 S3 p. S1-
1 p.
 artikel
33 In vitro-generation of potent antigen-presenting cells for immunotherapy: IL-4 is more effective than IFN-α Dauer, M.
 2001
 37 S3 p. S9-
1 p.
 artikel
34 In-vitro TNF-α effects on hematopoietic cell lines Jurisic, V
 2001
 37 S3 p. S10-
1 p.
 artikel
35 Low CD62L- expression in acute myeloid leukemia (AML) correlates with a bad cytogenetic risk Graf, M.
 2001
 37 S3 p. S9-
1 p.
 artikel
36 Magnetic drug targeting: biokinetic study and therapeutic efficacy Alexiou, Ch.
 2001
 37 S3 p. S11-
1 p.
 artikel
37 Mechanism of tumor eradication by transfer of sensitized T cells Shu, S.
 2001
 37 S3 p. S27-
1 p.
 artikel
38 Membrane expression of heat shock protein 70 (Hsp70) in hematological malignancies Gehrmann, M
 2001
 37 S3 p. S25-
1 p.
 artikel
39 Monocyte-derived dendritic cells to induce immunity to cancer Schuler, G.
 2001
 37 S3 p. S31-
1 p.
 artikel
40 Multicellular gastric cancer spheroids represent a valid model for pre-clinical testing of new therapeutic strategies Mayer, B.
 2001
 37 S3 p. S11-
1 p.
 artikel
41 Naked DNA and viral vectors as tumor vaccines Pecher, Gabriele
 2001
 37 S3 p. S20-
1 p.
 artikel
42 New chances for a renaissance of the HSCT- supported high-dose chemotherapy by the actively prevented tolerance-reinduction against inevitable residual tumor cells in the critical early phase of the treatment-related immuno-incompetence Leskovar, P.
 2001
 37 S3 p. S15-
1 p.
 artikel
43 Novel gene delivery systems Ulmer, Jeffrey
 2001
 37 S3 p. S20-
1 p.
 artikel
44 Our finding that the GvM and GvH effect are caused -at least partly- by different cell clones allows for the first time a selective GvM potentiation without a parallel GvHD induction Leskovar, P.
 2001
 37 S3 p. S13-
1 p.
 artikel
45 Our novel approaches (A) in the prevention of the acute and chronic graft-versus-host disease (GvHD) and — even more important — (B) in the eradication of pre-established GvHD could help to introduce clinically a variety of adoptive immunotherapies Leskovar, P.
 2001
 37 S3 p. S14-
1 p.
 artikel
46 Peroxisome proliferator activated receptor γ (PPARγ) agonists for treatment of neoplastic diseases - in vitro data and early clinical observations in chronic myelomnocytic leukemia (CMML) and in liposarcoma Denzlinger, C.
 2001
 37 S3 p. S11-
1 p.
 artikel
47 Phenotypic and functional changes of mouse dendritic cells after infection with vaccinia virus: comparison of three different strains Gabriel, P.
 2001
 37 S3 p. S35-
1 p.
 artikel
48 Recent advances in idiotype vaccination for the treatment of non-Hodgkin's lymphoma Veelken, Hendrik
 2001
 37 S3 p. S20-
1 p.
 artikel
49 Results of a phase II HPV vaccine trial with life recombinant vaccinia virus TA-HPV™ Kaufmann, AM
 2001
 37 S3 p. S20-
1 p.
 artikel
50 rViscumin, a novel anticancer agent — preclinical and clinical development status Wilhelm-Ogunbiyi, K.
 2001
 37 S3 p. S5-
1 p.
 artikel
51 Selective cytotoxicity of a diphtheria toxin-interleukin-3 fusion protein on acute myeloid leukemia stem cells Feuring-Buske, M.
 2001
 37 S3 p. S12-
1 p.
 artikel
52 Specific vaccination based on the Her2/neu proto-oncogene Kiessling, Rolf
 2001
 37 S3 p. S19-
1 p.
 artikel
53 Staphylococcal enterotoxin B- mediated T cell immune response induces apoptosis in bladder cancer cells Willert, Patricia L.
 2001
 37 S3 p. S10-
1 p.
 artikel
54 Systemic tumor regression mediated by effector T cells generated from perforin/IFN-γ double knock out mice is TNF dependent Poehlein, C.H.
 2001
 37 S3 p. S12-
1 p.
 artikel
55 T cell polarization in tumor vaccine draining lymph nodes (TVDLN) correlates with the tumor immunogenicity Winter, H.
 2001
 37 S3 p. S27-
1 p.
 artikel
56 Therapy of human tumors in NOD/SCID mice with patient derived re-activated memory T cells from bone marrow Feuerer, M.
 2001
 37 S3 p. S5-
1 p.
 artikel
57 The use of anti-CD3/CD28-dynabeads to restimulate human antigen specific T cells or expand naïve T cells Rasmussen, Anne-Marie
 2001
 37 S3 p. S13-
1 p.
 artikel
58 Tumor therapy : a gradual replacement of myeloablative preparative regimens by non-ablative ones reflects the recent trend towards an indirect, immunoregulatory intervention instead of the direct attack on the tumor cells. Some important clinical implications of our extensive animal experiments Leskovar, P.
 2001
 37 S3 p. S15-
1 p.
 artikel
59 Two important improvements of the conventional BMT and HSCT: (A) the routine use of a 1:1 mixture of D- and R- derived BMCS (or HSCS) preceded by the 1:1 mixture of D- and R- derived MIS effectors, and (B) the routine use of haploidentical MIS effectors, combined with BMT or HSCT Leskovar, P.
 2001
 37 S3 p. S14-
1 p.
 artikel
60 Vaccination with modified HER-2 molecules containing potent helper T cell epitopes induces protective immune responses in HER-2 transgenic mice Leach, D.R.
 2001
 37 S3 p. S26-
1 p.
 artikel
61 Vaccination with peptides derived from the extracellular domain of Her-2/neu elicits specific humoral and cellular immune responses in mice Jasinska, J.
 2001
 37 S3 p. S26-
1 p.
 artikel
62 Vaccination with T cell-defined antigens: biological basis and clinical applications Parmiani, Giorgio
 2001
 37 S3 p. S19-
1 p.
 artikel
                             62 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland